Gut bacteria transplant before stem cell transplant
Part of Blood & lymphatic, Cancer, Immune system & allergy clinical trials.
This trial tests whether giving a transplant of healthy gut bacteria (fecal microbiota transplant) before a stem cell transplant can improve outcomes for people with certain blood cancers or bone marrow disorders.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You are 18 years or older with a blood cancer or bone marrow disorder like ALL, AML, MDS, or chronic myeloid leukemia in blast phase.
- Your disease should be in remission (less than 5% blasts in bone marrow) after chemotherapy.
- You have completed at least 2 rounds of intensive chemotherapy.
- You've taken broad-spectrum antibiotics within the last 3 months.
- Your doctor says you are healthy enough to undergo a stem cell transplant.
- You must be willing to take capsules containing gut bacteria from healthy donors.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This Phase 2 study tests a strong (myeloablative) stem cell transplant using donor stem cells (allogeneic transplant) for certain blood and bone marrow cancers. The goal is to see how well this approach works and whether it can improve outcomes for people who need transplant-level treatment.
This Phase 2 trial tests whether a specific stem cell transplant method (from a related “half-matched” donor) plus conditioning chemo and radiation can improve outcomes for several blood cancers. It may help people whose cancer is in remission but still considered high risk, or those who have had limited response after prior treatment.
This trial tests a stem cell transplant using milder chemotherapy (treosulfan and fludarabine) followed by a drug called cyclophosphamide to prevent graft-versus-host disease. It aims to make transplant safer for people with blood diseases who cannot handle standard high-dose chemotherapy.
This trial tests a combination of two chemotherapy drugs given before a stem cell transplant to help people with acute myeloid leukemia (AML) that has not responded to treatment or has come back. The goal is to improve the success of the transplant.
This trial is testing a more targeted way to deliver radiation before a stem cell transplant, aiming to reduce side effects while helping the new cells engraft. It includes two different radiation doses, one for first-time transplant patients and another for those who have relapsed after a prior transplant.
This study tests a way to lower the chance of graft-versus-host disease (a common side effect of stem cell transplants) by removing certain immune cells from the donor's stem cells before they are given to you. It is for older patients with acute leukemia or MDS who are getting a transplant.
Hear when a new Acute Leukemia of Ambiguous Lineage trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.